About aTyr Pharma, Inc.
Clinical-stage biotech developing therapeutics based on tRNA synthetase biology. Micro-cap, no dividend, no revenue, extreme binary risk around trial readouts. Thin liquidity, wide spreads — options rarely viable for consistent CSP income.
Biotechnology